

# Alice S Chen-Plotkin

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4017521/alice-s-chen-plotkin-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

97  
papers

9,680  
citations

47  
h-index

98  
g-index

116  
ext. papers

12,078  
ext. citations

9.9  
avg, IF

5.84  
L-index

#	Paper	IF	Citations
97	Reply to: "Age-Adjusted Serum Neurofilament Predicts Cognitive Decline in Parkinson's Disease (MARK-PD)".. <i>Movement Disorders</i> , <b>2022</b> , 37, 436-437	7	
96	Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration.. <i>Molecular Neurodegeneration</i> , <b>2022</b> , 17, 29	19	1
95	Abnormal B-Cell and Tfh-Cell Profiles in Patients With Parkinson Disease: A Cross-sectional Study.. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2022</b> , 9,	9.1	2
94	Neurofilament Light Chain Related to Longitudinal Decline in Frontotemporal Lobar Degeneration. <i>Neurology: Clinical Practice</i> , <b>2021</b> , 11, 105-116	1.7	2
93	Whole Clinic Research Enrollment in Parkinson's Disease: The Molecular Integration in Neurological Diagnosis (MIND) Study. <i>Journal of Parkinsons Disease</i> , <b>2021</b> , 11, 757-765	5.3	1
92	Psychometric Properties of the Clinical Dementia Rating Scale Sum of Boxes in Parkinson's Disease. <i>Journal of Parkinsons Disease</i> , <b>2021</b> , 11, 737-745	5.3	1
91	L1CAM is not associated with extracellular vesicles in human cerebrospinal fluid or plasma. <i>Nature Methods</i> , <b>2021</b> , 18, 631-634	21.6	30
90	TMEM106B modifies TDP-43 pathology in human ALS brain and cell-based models of TDP-43 proteinopathy. <i>Acta Neuropathologica</i> , <b>2021</b> , 142, 629-642	14.3	3
89	LRRK2 and survival in progressive supranuclear palsy. <i>Lancet Neurology, The</i> , <b>2021</b> , 20, 83-84	24.1	1
88	Of mice and men: What a mouse model of microglial C9ORF72 deficiency does-and does not-tell us about human neurodegenerative diseases. <i>Neuron</i> , <b>2021</b> , 109, 2203-2204	13.9	
87	Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease. <i>Movement Disorders</i> , <b>2021</b> ,	7	3
86	A growth-factor-activated lysosomal K channel regulates Parkinson's pathology. <i>Nature</i> , <b>2021</b> , 591, 431-437	37.4	15
85	Subjective Cognitive Complaint in Parkinson's Disease Patients With Normal Cognition: Canary in the Coal Mine?. <i>Movement Disorders</i> , <b>2020</b> , 35, 1618-1625	7	12
84	New York City COVID-19 resident physician exposure during exponential phase of pandemic. <i>Journal of Clinical Investigation</i> , <b>2020</b> , 130, 4726-4733	15.9	40
83	Resident physician exposure to novel coronavirus (2019-nCoV, SARS-CoV-2) within New York City during exponential phase of COVID-19 pandemic: Report of the New York City Residency Program Directors COVID-19 Research Group <b>2020</b> ,		9
82	Omics in Neurodegenerative Disease: Hope or Hype?. <i>Trends in Genetics</i> , <b>2020</b> , 36, 152-159	8.5	20
81	ADNC-RS, a clinical-genetic risk score, predicts Alzheimer's pathology in autopsy-confirmed Parkinson's disease and Dementia with Lewy bodies. <i>Acta Neuropathologica</i> , <b>2020</b> , 140, 449-461	14.3	3

80	Tau pathology associates with in vivo cortical thinning in Lewy body disorders. <i>Annals of Clinical and Translational Neurology</i> , <b>2020</b> , 7, 2342-2355	5.3	8
79	TMEM106B Effect on cognition in Parkinson disease and frontotemporal dementia. <i>Annals of Neurology</i> , <b>2019</b> , 85, 801-811	9.4	23
78	Cognitive Functional Abilities in Parkinson's Disease: Agreement Between Patients and Informants. <i>Movement Disorders Clinical Practice</i> , <b>2019</b> , 6, 440-445	2.2	9
77	Characterization of Parkinson's disease using blood-based biomarkers: A multicohort proteomic analysis. <i>PLoS Medicine</i> , <b>2019</b> , 16, e1002931	11.6	17
76	AAV-Mediated Progranulin Delivery to a Mouse Model of Progranulin Deficiency Causes T Cell-Mediated Toxicity. <i>Molecular Therapy</i> , <b>2019</b> , 27, 465-478	11.7	29
75	Elevated CSF GAP-43 is Alzheimer's disease specific and associated with tau and amyloid pathology. <i>Alzheimer's and Dementia</i> , <b>2019</b> , 15, 55-64	1.2	50
74	Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders. <i>JAMA Neurology</i> , <b>2019</b> , 76, 318-325	17.2	94
73	CSF tau and Amyloid predict cerebral synucleinopathy in autopsied Lewy body disorders. <i>Neurology</i> , <b>2018</b> , 90, e1038-e1046	6.5	43
72	Genetic Modifiers in Neurodegeneration. <i>Current Genetic Medicine Reports</i> , <b>2018</b> , 6, 11-19	2.2	8
71	The Post-GWAS Era: From Association to Function. <i>American Journal of Human Genetics</i> , <b>2018</b> , 102, 717-730	13.0	294
70	Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology. <i>Acta Neuropathologica</i> , <b>2018</b> , 136, 363-376	14.3	83
69	Cerebrospinal fluid Synuclein contributes to the differential diagnosis of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2018</b> , 14, 1052-1062	1.2	27
68	Unlocking the mystery of biomarkers: A brief introduction, challenges and opportunities in Parkinson Disease. <i>Parkinsonism and Related Disorders</i> , <b>2018</b> , 46 Suppl 1, S15-S18	3.6	14
67	Finding useful biomarkers for Parkinson's disease. <i>Science Translational Medicine</i> , <b>2018</b> , 10,	17.5	69
66	Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. <i>Brain</i> , <b>2018</b> , 141, 2181-2193	11.2	245
65	APOE, thought disorder, and SPARE-AD predict cognitive decline in established Parkinson's disease. <i>Movement Disorders</i> , <b>2018</b> , 33, 289-297	7	24
64	Updating Our Definitions of Parkinson's Disease for a Molecular Age. <i>Journal of Parkinson's Disease</i> , <b>2018</b> , 8, S53-S57	5.3	6
63	Aberrant activation of non-coding RNA targets of transcriptional elongation complexes contributes to TDP-43 toxicity. <i>Nature Communications</i> , <b>2018</b> , 9, 4406	17.4	26

62	Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials. <i>Movement Disorders</i> , <b>2017</b> , 32, 319-324	7	111
61	Prediction of cognition in Parkinson's disease with a clinical-genetic score: a longitudinal analysis of nine cohorts. <i>Lancet Neurology</i> , <b>2017</b> , 16, 620-629	24.1	98
60	Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. <i>Neurology</i> , <b>2017</b> , 89, 88-100	6.5	1691
59	Neuropsychological Subgroups in Non-Demented Parkinson's Disease: A Latent Class Analysis. <i>Journal of Parkinson's Disease</i> , <b>2017</b> , 7, 385-395	5.3	15
58	A Dementia-Associated Risk Variant near TMEM106B Alters Chromatin Architecture and Gene Expression. <i>American Journal of Human Genetics</i> , <b>2017</b> , 101, 643-663	11	46
57	Regional brain amyloid- $\beta$ accumulation associates with domain-specific cognitive performance in Parkinson disease without dementia. <i>PLoS ONE</i> , <b>2017</b> , 12, e0177924	3.7	25
56	Vitamin D in the Parkinson Associated Risk Syndrome (PARS) study. <i>Movement Disorders</i> , <b>2017</b> , 32, 1636-1640	12	
55	Statins and Cognition in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , <b>2017</b> , 7, 661-667	5.3	10
54	Common variant rs356182 near SNCA defines a Parkinson's disease endophenotype. <i>Annals of Clinical and Translational Neurology</i> , <b>2017</b> , 4, 15-25	5.3	26
53	Parkinson's disease biomarkers: perspective from the NINDS Parkinson's Disease Biomarkers Program. <i>Biomarkers in Medicine</i> , <b>2017</b> , 11, 451-473	2.3	33
52	Circulating brain-enriched microRNAs as novel biomarkers for detection and differentiation of neurodegenerative diseases. <i>Alzheimer's Research and Therapy</i> , <b>2017</b> , 9, 89	9	85
51	Association of GBA Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease. <i>JAMA Neurology</i> , <b>2016</b> , 73, 1217-1224	17.2	120
50	GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease. <i>Movement Disorders</i> , <b>2016</b> , 31, 95-102	7	113
49	CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study. <i>Acta Neuropathologica</i> , <b>2016</b> , 131, 935-49	14.3	138
48	An Alzheimer's Disease-Derived Biomarker Signature Identifies Parkinson's Disease Patients with Dementia. <i>PLoS ONE</i> , <b>2016</b> , 11, e0147319	3.7	18
47	The NINDS Parkinson's disease biomarkers program. <i>Movement Disorders</i> , <b>2016</b> , 31, 915-23	7	56
46	Plasma EGF and cognitive decline in Parkinson's disease and Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , <b>2016</b> , 3, 346-55	5.3	26
45	Defining and validating a short form Montreal Cognitive Assessment (s-MoCA) for use in neurodegenerative disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2016</b> , 87, 1303-1310	5.5	41

44	Increased expression of the frontotemporal dementia risk factor TMEM106B causes C9orf72-dependent alterations in lysosomes. <i>Human Molecular Genetics</i> , <b>2016</b> , 25, 2681-2697	5.6	38
43	Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study. <i>Lancet Neurology</i> , <b>2015</b> , 14, 1002-9	24.1	141
42	Longitudinal study of normal cognition in Parkinson disease. <i>Neurology</i> , <b>2015</b> , 85, 1276-82	6.5	144
41	Caregiver report of apathy predicts dementia in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , <b>2015</b> , 21, 992-5	3.6	24
40	Lower plasma apolipoprotein A1 levels are found in Parkinson's disease and associate with apolipoprotein A1 genotype. <i>Movement Disorders</i> , <b>2015</b> , 30, 805-12	7	29
39	Reply to letter: Plasma fasting cholesterol profiles and age at onset in Parkinson's disease. <i>Movement Disorders</i> , <b>2015</b> , 30, 1975-6	7	
38	Plasma apolipoprotein A1 associates with age at onset and motor severity in early Parkinson's disease patients. <i>Movement Disorders</i> , <b>2015</b> , 30, 1648-56	7	50
37	Blood-based biomarkers for Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , <b>2014</b> , 20 Suppl 1, S99-103	3.6	88
36	TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions. <i>Acta Neuropathologica</i> , <b>2014</b> , 127, 407-18	14.3	97
35	Unbiased approaches to biomarker discovery in neurodegenerative diseases. <i>Neuron</i> , <b>2014</b> , 84, 594-607	13.9	40
34	A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank. <i>Alzheimers and Dementia</i> , <b>2014</b> , 10, 477-484.e1	1.2	118
33	What can biomarkers tell us about cognition in Parkinson's disease?. <i>Movement Disorders</i> , <b>2014</b> , 29, 622-33	3.3	48
32	Conversion between mini-mental state examination, montreal cognitive assessment, and dementia rating scale-2 scores in Parkinson's disease. <i>Movement Disorders</i> , <b>2014</b> , 29, 1809-15	7	62
31	Clinical and biochemical differences in patients having Parkinson disease with vs without GBA mutations. <i>JAMA Neurology</i> , <b>2013</b> , 70, 852-8	17.2	87
30	Association of cerebrospinal fluid Aβ <sub>1-42</sub> , T-tau, P-tau181, and Synuclein levels with clinical features of drug-naive patients with early Parkinson disease. <i>JAMA Neurology</i> , <b>2013</b> , 70, 1277-87	17.2	252
29	Expression of TMEM106B, the frontotemporal lobar degeneration-associated protein, in normal and diseased human brain. <i>Acta Neuropathologica Communications</i> , <b>2013</b> , 1, 36	7.3	19
28	Development and validation of pedigree classification criteria for frontotemporal lobar degeneration. <i>JAMA Neurology</i> , <b>2013</b> , 70, 1411-7	17.2	87
27	Association of plasma C-reactive protein levels with the diagnosis of Alzheimer's disease. <i>Journal of the Neurological Sciences</i> , <b>2013</b> , 333, 9-12	3.2	43

26	APOE $\epsilon$ increases risk for dementia in pure synucleinopathies. <i>JAMA Neurology</i> , <b>2013</b> , 70, 223-8	17.2	243
25	Plasma apolipoprotein A1 as a biomarker for Parkinson disease. <i>Annals of Neurology</i> , <b>2013</b> , 74, 119-27	9.4	90
24	Modeling kinetic rate variation in third generation DNA sequencing data to detect putative modifications to DNA bases. <i>Genome Research</i> , <b>2013</b> , 23, 129-41	9.7	63
23	Genetic influences on cognitive decline in Parkinson's disease. <i>Movement Disorders</i> , <b>2012</b> , 27, 512-8	7	100
22	TMEM106B, the risk gene for frontotemporal dementia, is regulated by the microRNA-132/212 cluster and affects progranulin pathways. <i>Journal of Neuroscience</i> , <b>2012</b> , 32, 11213-27	6.6	143
21	Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. <i>Neurology</i> , <b>2012</b> , 79, 897-905	6.5	175
20	Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice. <i>Journal of Clinical Investigation</i> , <b>2011</b> , 121, 726-38	15.9	284
19	Risk genotypes at TMEM106B are associated with cognitive impairment in amyotrophic lateral sclerosis. <i>Acta Neuropathologica</i> , <b>2011</b> , 121, 373-80	14.3	82
18	Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. <i>Annals of Neurology</i> , <b>2011</b> , 69, 655-63	9.4	103
17	Genetic and clinical features of progranulin-associated frontotemporal lobar degeneration. <i>Archives of Neurology</i> , <b>2011</b> , 68, 488-97		93
16	PolyQ repeat expansions in ATXN2 associated with ALS are CAA interrupted repeats. <i>PLoS ONE</i> , <b>2011</b> , 6, e17951	3.7	64
15	Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. <i>Nature</i> , <b>2010</b> , 466, 1069-75	50.4	844
14	Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. <i>Nature Genetics</i> , <b>2010</b> , 42, 234-9	36.3	361
13	Age-correlated gene expression in normal and neurodegenerative human brain tissues. <i>PLoS ONE</i> , <b>2010</b> , 5, e13098	3.7	28
12	The spectrum of mutations in progranulin: a collaborative study screening 545 cases of neurodegeneration. <i>Archives of Neurology</i> , <b>2010</b> , 67, 161-70		143
11	Hypertrophic pachymeningitis and cerebral venous sinus thrombosis in inflammatory bowel disease. <i>Journal of Clinical Neuroscience</i> , <b>2010</b> , 17, 1454-6	2.2	14
10	TAR DNA-binding protein 43 in neurodegenerative disease. <i>Nature Reviews Neurology</i> , <b>2010</b> , 6, 211-20	15	322
9	Brain progranulin expression in GRN-associated frontotemporal lobar degeneration. <i>Acta Neuropathologica</i> , <b>2010</b> , 119, 111-22	14.3	56

8	Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment. <i>Acta Neuropathologica</i> , <b>2010</b> , 119, 669-78	14.3	140
7	Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease. <i>Acta Neuropathologica</i> , <b>2010</b> , 120, 385-99	14.3	65
6	Expression of TDP-43 C-terminal Fragments in Vitro Recapitulates Pathological Features of TDP-43 Proteinopathies. <i>Journal of Biological Chemistry</i> , <b>2009</b> , 284, 8516-24	5.4	262
5	TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. <i>Lancet Neurology, The</i> , <b>2008</b> , 7, 409-16	24.1	542
4	Variations in the progranulin gene affect global gene expression in frontotemporal lobar degeneration. <i>Human Molecular Genetics</i> , <b>2008</b> , 17, 1349-62	5.6	96
3	Delayed leukoencephalopathy after hypoxic-ischemic injury. <i>Archives of Neurology</i> , <b>2008</b> , 65, 144-5		17
2	Demyelinating polyneuropathy and herpes simplex lumbosacral radiculitis in a patient with chronic HIV infection. <i>Aids</i> , <b>2007</b> , 21, 1663-4	3.5	5
1	Decreased association of the transcription factor Sp1 with genes downregulated in Huntington's disease. <i>Neurobiology of Disease</i> , <b>2006</b> , 22, 233-41	7.5	92